<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43739">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02155725</url>
  </required_header>
  <id_info>
    <org_study_id>FIDEL</org_study_id>
    <secondary_id>2013-002484-26</secondary_id>
    <nct_id>NCT02155725</nct_id>
  </id_info>
  <brief_title>Fibrinogen in Haemorrhage of Delivery</brief_title>
  <acronym>FIDEL</acronym>
  <official_title>Study on the Efficacy and Safety of a Therapeutic Strategy of PPH Comparing Early Administration of Human Fibrinogen vs Placebo in Patients Treated With IV Prostaglandins Following Vaginal Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoire français de Fractionnement et de Biotechnologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoire français de Fractionnement et de Biotechnologies</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>France: Committee for the Protection of Personnes</authority>
    <authority>France: Conseil National de l'Ordre des Médecins</authority>
    <authority>France: French Data Protection Authority</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the benefits of a therapeutic strategy that associates
      an early administration of human fibrinogen concentrate in the management of PPH on the
      reduction of bleeding after the initiation of prostaglandins intravenous infusion, following
      vaginal delivery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomised, double-blind,multicenter, placebo-controlled study
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of patients losing at least 4 g/dl of Hb, and/or requiring the transfusion of at least 2 units of packed RBCs within the 48 hours following the administration of IMP.</measure>
    <time_frame>48h following IMP administration</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evolution of haemorrhage</measure>
    <time_frame>48h following IMP administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of patients losing at least 4g/dL and 3g/dL of Hb with regards to the Hb reference level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients requiring at least one hemostatic intervention</measure>
    <time_frame>48h following IMP administration</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal morbi-mortality</measure>
    <time_frame>at each follow-up assessment , up to 6 +/- 2 weeks after delivery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Length of stay in resuscitation and/or in intensive care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma fibrinogen level between H0 and Day 2, after early administration</measure>
    <time_frame>48h following IMP administration</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with at least one AE and/or SAE</measure>
    <time_frame>at each follow-up assessment, up to 6 +/- 2 weeks after delivery</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of haemorrhage</measure>
    <time_frame>48h following IMP administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of patients losing at least 4g/dL with regards to Hb level measured at inclusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of haemorrhage</measure>
    <time_frame>48h following IMP administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of patients requiring the transfusion of at least 2 units of packed RBCs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of haemorrhage</measure>
    <time_frame>48h following IMP administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of units of transfused blood products</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of haemorrhage</measure>
    <time_frame>48h following IMP administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>Total blood loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal morbi-mortality</measure>
    <time_frame>at each follow-up assessment, up to 6 +/- 2 weeks after delivery</time_frame>
    <safety_issue>No</safety_issue>
    <description>SOFA score in women transferred to resuscitation and/or intensive care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal morbi-mortality</measure>
    <time_frame>at each follow-up assessment, up to 6 +/- 2 weeks after delivery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Death during the study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">434</enrollment>
  <condition>Post-Partum Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Human Fibrinogen concentrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 vials (200ml) / 3g intravenous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 vials (200ml)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human Fibrinogen concentrate</intervention_name>
    <description>Injection as soon as possible and within 30 min following the start of prostaglandin infusion</description>
    <arm_group_label>Human Fibrinogen concentrate</arm_group_label>
    <other_name>Clottafact, LFB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>As soon as possible and within 30 min following the start of prostaglandin infusion</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed and dated informed consent form

          -  Vaginal delivery

          -  PPH requiring IV administration of prostaglandins

          -  At least one available result of Hb level during the third trimester of pregnancy

          -  18-year-old female patients and older

          -  Covered by healthcare insurance in accordance with local requirements

        Exclusion Criteria:

          -  Caesarean section

          -  Haemostatic intervention (as ligation, embolization or hysterectomy) already decided
             at the time of inclusion

          -  Known placenta praevia or accreta

          -  Hb level &lt; 10g/dl during the third trimester of pregnancy

          -  History of venous or arterial thromboembolic event

          -  Known inherited bleeding or thrombotic disorders

          -  Treatment with low-molecular-weight heparin (LMWH) within 24 hours prior to the
             inclusion

          -  Treatment with acetylsalicylic acid within 5 days prior to the inclusion

          -  Treatment with vitamin K antagonists within 7 days prior to the inclusion

          -  Administration of fibrinogen concentrate within 48 hours prior to the inclusion

          -  Administration of FFP, platelets units or prohaemostatic drugs, tranexamic acid and
             rFVIIa or prothrombin complex concentrates (PCC) within 48 hours prior to the
             inclusion

          -  Administration of RBCs within 3 months prior to the inclusion

          -  Participation in another interventional clinical study within 30 days prior to the
             inclusion

          -  Previous inclusion/enrolment in the present clinical study

          -  Known history of hypersensitivity or other severe reaction to any component of
             Clottafact® or placebo

          -  Minors, majors under guardianship, persons staying in health or social institutes and
             people deprived of their freedom

          -  Known drug or alcohol abuse

          -  Patients whose use of concomitant medication may interfere with the interpretation of
             data

          -  Any other current significant medical condition that might interfere with treatment
             evaluation according to the investigator's judgement

          -  Patients who are unlikely to survive through the treatment period and evaluation

          -  Patients transferred from another service
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne-Sophie DUCLOY-BOUTHORS, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maternité Jeanne de Flandre - 59037 LILLE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frédéric MERCIER, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>Hôpital Antoine Béclère - 92140 CLAMART</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexandre MIGNON, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>Hôpital Cochin - 75014 PARIS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cyril HUISSOUD, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Hôpital Croix Rousse -69004 LYON</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne-Sophie DUCLOY-BOUTHORS, Dr</last_name>
    <phone>+33 3 20 44 63 15</phone>
    <email>anne-sophie.ducloy@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sigismond LASOCKI, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Femme Mère Enfant</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Dominique CHASSARD, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Antoine Béclère</name>
      <address>
        <city>Clamart</city>
        <zip>92141</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Frédéric MERCIER, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Louis Mourier</name>
      <address>
        <city>Colombes</city>
        <zip>92701</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Hawa KEITA-MEYER, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre</name>
      <address>
        <city>Le Kremlin-bicetre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Toni KFOURY, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Lens</name>
      <address>
        <city>Lens</city>
        <zip>62307</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jihad MALLAT, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Lille, Maternité Jeanne de Flandre</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Julien COROUGE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Nathalie NATHAN, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Françoise BROISIN, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Estelle MORAU, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maternité Régionale Universitaire de Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Florence VIAL, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alexandre MIGNON, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Francis BONNET, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Armand Trousseau</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Agnes RIGOUZZO, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Reims, Hôpital Maison Blanche</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Marc MALINOVSKY, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Pierre DIEMUNSCH, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marc FISCHLER, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Paul de Viguier - Site Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Françoise BAYOUMEU, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Christophe MANGIN, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Valenciennes</name>
      <address>
        <city>Valenciennes</city>
        <zip>59300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Laurent CHONOW, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>June 3, 2014</lastchanged_date>
  <firstreceived_date>May 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PPH</keyword>
  <keyword>fibrinogen</keyword>
  <keyword>vaginal delivery</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postpartum Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
